Müller ML, Butler J, Heidecker B (2020) Emerging therapies in transthyretin amyloidosis – a new wave of hope after years of stagnancy? Eur J Heart Fail 22(1):39–53

Article  PubMed  Google Scholar 

Burton A, Castaño A, Bruno M et al (2021) Drug discovery and development in rare diseases: taking a closer look at the tafamidis story. Drug Des Devel Ther 15:1225–1243

Article  PubMed  PubMed Central  Google Scholar 

Mundayat R, Stewart M, Alvir J et al (2018) Positive effectiveness of tafamidis in delaying disease progression in transthyretin familial amyloid polyneuropathy up to 2 years: an analysis from the transthyretin amyloidosis outcomes survey (THAOS). Neurol Ther 7(1):87–101

Article  PubMed  PubMed Central  Google Scholar 

Ando Y, Coelho T, Berk JL et al (2013) Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 8(1):1–18

Article  Google Scholar 

Park J, Egolum U, Parker S et al (2020) Tafamidis: a first-in-class transthyretin stabilizer for transthyretin amyloid cardiomyopathy. Ann Pharmacother 54(5):470–477

Article  PubMed  Google Scholar 

Rapezzi C, Elliott P, Damy T et al (2021) Efficacy of Tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT. JACC Hear Fail 9(2):115–123

Article  Google Scholar 

Coelho T, Merlini G, Bulawa CE et al (2016) Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther 5(1):1–25

Article  PubMed  PubMed Central  Google Scholar 

Lockwood PA, Le VH, O’Gorman MT et al (2020) The bioequivalence of tafamidis 61-mg free acid capsules and Tafamidis meglumine 4 × 20-mg capsules in healthy volunteers. Clin Pharmacol Drug Dev 9(7):849–854

Article  CAS  PubMed  PubMed Central  Google Scholar 

Monteiro C, Mesgazardeh JS, Anselmo J et al (2019) Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight 4(12):1–17

Article  Google Scholar 

Gentile L, Tournev I, Amass L et al (2021) Phenotypic differences of Glu89Gln genotype in ATTR amyloidosis from endemic loci: update from THAOS. Cardiol Ther 10(2):481–490

Article  PubMed  PubMed Central  Google Scholar 

Rapezzi C, Quarta CC, Obici L et al (2013) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 34(7):520–528

Article  CAS  PubMed  Google Scholar 

Cortese A, Vita G, Luigetti M et al (2016) Monitoring effectiveness and safety of tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol 263(5):916–924

Article  CAS  PubMed  Google Scholar 

Gagliardi C, Gospodinova M, Longhi S et al (2015) Glu89Gln transthyretin-related amyloidosis in Italy and Bulgaria: does geographic area influence phenotype beyond the shared mutation? Orphanet J Rare Dis 10(S1):P23. Proceedings of the First European Congress on Hereditary ATTR amyloidosis; November 2–3, 2015; Paris, France

Milanov I, Tournev I (2019) National consensus for diagnosis, treatment, follow-up and prevention of hereditary transthyretin amyloidosis. Bulgarian Neurology 20:1–30 (Bulgarian)

Gospodinova M, Sarafov S, Guergueltcheva V et al (2015) Cardiomyopathy and peripheral polyneuropathy severity in patients with Glu89Gln mutation at the time of diagnosis. Orphanet J Rare Dis 10(S1):P59. Proceedings of the First European Congress on Hereditary ATTR amyloidosis; November 2–3, 2015; Paris, France

Gospodinova M, Sarafov S, Guergueltcheva V et al (2015) Cardiac involvement and clinical follow up of patients with hereditary transthyretin related amyloidosis associated with Glu89Gln mutation. Orphanet J Rare Dis 10 (S1):P54. Proceedings of the First European Congress on Hereditary ATTR amyloidosis; November 2–3, 2015; Paris, France

Gospodinova M, Sarafov S, Chamova T et al (2020) Cardiac involvement, morbidity and mortality in hereditary transthyretin amyloidosis because of p.Glu89Gln mutation. J Cardiovasc Med (Hagerstown) 21:688–695

Article  CAS  PubMed  Google Scholar 

Nakov R, Sarafov S, Nakov V et al (2019) Gastrointestinal manifestations in hereditary transthyretin amyloidosis associated with Glu89Gln mutation. J Gastrointest Liver Dis 28(4):421–426

Article  Google Scholar 

Smerikarova M, Bozhanov S, Maslarska V et al (2022) Determination of tafamidis plasma concentrations in amyloidosis patients with Glu89Gln mutation by HPLC-UV detection. J Chrom Sci 60(9):840–847

Article  CAS  Google Scholar 

Sarafov S (2020) Clinical-genetic and epidemiological studies in transthyretin familial amyloid polyneuropathy and in hereditary and familial amyotrophic lateral sclerosis in Bulgaria. Dissertation, Medical University-Sofia